Description
Tirzepatide is a once-weekly subcutaneous injection. As a dual receptor agonist, it stimulates both GLP-1 and GIP receptors, slowing digestion and reducing appetite.
Key Information About Tirzepatide:
-
- Mechanism: It mimics GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) hormones to manage blood sugar and increase satiety.
- Administration: It is a synthetic peptide injected once a week.
- Weight Loss Efficacy:
Studies showed significant weight reduction, with higher doses (15 mg) leading to approximately 15% to 21% body weight loss in 72 weeks.
- Dosage: Typical dosage starts low and increases, with maximum doses often being 15 mg weekly.
- Side Effects: Nausea, diarrhea, vomiting, constipation, and stomach pain are common, particularly during dose increases.
- Contraindications: It is not for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Common Food and Drink to Avoid:
-
To mitigate side effects, it is recommended to avoid:
-
Fried, greasy, or high-fat foods.
-
Sugary foods and drinks.
-
Refined carbohydrates.
-
Excessive alcohol.
Patients reach and maintain lower HbA1c and weight levels.
Disclaimer: This information is for educational purposes based on research studies and does not constitute medical advice. Consult a healthcare provider before starting any peptide therapy.
Reviews
There are no reviews yet.